🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  2. Cariprazine

    AbbVie

    Bipolar I Disorder

    phase 3 small molecule completed

    1 trial

  3. Carrellizumab + Capecitabine

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  4. Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat

    Lacuna Pharma Pty Ltd

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

  5. Casodex® 50 mg Film-coated Tablets, ANANDRON 150 mg, comprimé, Flutamide 250 mg Tablets, Xtandi - 40 mg soft capsules

    Ningbo Cancer Hospital

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  6. Ceftazidime-avibactam

    Pfizer

    Complicated Intra-abdominal Infection

    phase 3 small molecule completed

    1 trial

  7. Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE

    The George Institute

    CHRONIC OMALGIA

    phase 3 small molecule active

    1 trial

  8. CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets

    Hoffmann-La Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

  9. Cemdisiran, Pozelimab

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Recurrent Lung Non-Small Cell Carcinoma

    phase 3 mab active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 3 small molecule active

    7 trials

  12. Cemiplimab

    Regeneron UK Limited

    Squamous Cell Carcinoma (SCC)

    phase 3 small molecule completed

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  14. Cendakimab

    Celgene Europe Limited

    Eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  15. Cenestin 0.3 mg Tablets

    Teva Pharma GmbH

    Hot Flashes

    phase 3 small molecule completed

    1 trial

  16. Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

    Sanofi-aventis Healthcare Pty Ltd

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  17. Cetuximab

    Amgen

    Metastatic Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  18. Chemotherapy + avelumab followed by avelumab + talazoparib

    Pfizer

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  19. Chestnut Bloomington Outpatient (CBOP)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  20. Cibinqo 100 mg film-coated tablets, Placebo for Abrocitinib 100mg tablet

    Pfizer Australia Pty Ltd

    Moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  21. Cilostazol-Elpen 100 mg Tabletten, Placebo de Cilostazol-Elpen 100mg, comprimé

    Pari Pharma GmbH

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  22. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  23. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  24. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources